BC
VERA icon

Bridgefront Capital’s Vera Therapeutics VERA Stock Holding History

Bridgefront Capital’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$310K Buy
+7,715
New +$332K 0.08% 387

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridgefront Capital's VERA Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Vera Therapeutics (VERA) in Q1 2026: 7,715 shares worth $310K. The stake represents 0.08% of the portfolio and ranks #387 among its holdings.

229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Bridgefront Capital held 7,715 shares of Vera Therapeutics worth $310K as of Q1 2026.
  • Vera Therapeutics was a new Bridgefront Capital position in Q1 2026.
  • Vera Therapeutics made up 0.08% of Bridgefront Capital's portfolio in Q1 2026, its #387 holding.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.